oral compounded semaglutide reviews for Women SkinnyRx | Compounded Sublingual Semaglutide

SeekPeptides members access detailed dosing protocols, calculators , and a community of experienced researchers who have navigated these exact questions

TRIUMPH-1 has closed: The main obesity trial (NCT05929066) completed enrollment in April 2026

*This medication is a compounded product and is not approved by the FDA

In Phase 2 trials, retatrutide produced approximately 24% mean weight loss at 48 weeks at 12 mg, compared with about 22.5% for tirzepatide at 15 mg in the SURMOUNT-1 trial though direct head-to-head data is not yet available

Administration occurs subcutaneously, typically in the abdominal area, thigh, or upper arm, rotating injection sites to prevent tissue irritation

Over 26 weeks, heavy drinking days fell by 41.1 percentage points in the semaglutide group versus 26.4 in the placebo group, a 13.7-point treatment difference that reached statistical significance